Provided herein are compositions to treat Clostridioides difficile (C. difficile),
Mycobacterium tuberculosis (M.
tuberculosis) and
Enterococcus faecalis (E. faecalis). These compositions are related to the known compounds (+)-Puupehenone and (+)-ent-Chromazonarol, which are both naturally occurring products. The new compositions were shown to potently inhibit both growth and
toxin production of C. difficile as well as inhibit the growth and survival of both replicating and dormant M.
tuberculosis. In the United States the C. difficile burden is approximately 453,000 hospital cases and 29,000 deaths annually. Globally, about 10 million people fall ill from tuberculosis and 1.4 million died from the
disease. In addition, the known compound (+)-ent-Chromazonarol (10) was found for the first time to strongly inhibit the growth of E. faecalis. E. faecalis has grown
drug resistant to
vancomycin. In 2017,
Vancomycin-Resistant Enterococci (VRE) caused an estimated 54,500 infections among
hospitalized patients and 5,400 estimated deaths in the United States.